IMM-6-415

· Immuneering Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMM-6-415, covering 2025-05-28 to 2025-05-28. Get the full timeline:

Most recent: Clinical Trial Update: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors [Phase 1, Phase 2]